Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

A Phase 1 Study to Determine the Safety and Pharmacokinetics of Brivanib in Chinese Subjects With Advanced Hepatocellular Carcinoma (HCC)

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of Brivanib in Chinese subjects with Advanced Hepatocellular Carcinoma (HCC).

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Subjects with:

• Confirmed Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)
• Not having received prior systemic treatment for advanced HCC
• Normal or moderately impaired liver function (Child-Pugh Class A or B (CP total score of ≤ 7))
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

Subjects with:

• Brain metastasis or evidence of leptomeningeal disease
• History of impaired brain function (encephalopathy) or active heart disease
• Unmanageable fluid in the abdomen (ascites)
• Bleeding esophageal or gastric varices within 2 months prior to inclusion